CVRdatabase
Menu

AGC Biologics A/S

Public limited companyCVR 25950941SøborgActive

AGC Biologics A/S is a public limited company, based in Søborg, active in manufacture of pharmaceutical preparations, founded in 2001. The company made a loss in both 2024 and 2025, most recently DKK 328m. Operations are spread over 4 production units. With 1,294 employees, the company is about 129 times larger than the industry median.

Follow
PDF reportCompare

Key figures · financial year 2025

RevenueDKK 2bn−2.8% vs. 2024
Net profit−DKK 328m−185.2% vs. 2024
EquityDKK 312m−51.2% vs. 2024
Employees1,294latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • Gross profit fell 157% (2024 → 2025), to −DKK 91.2m.
  • Revenue fell 3% (2024 → 2025), to DKK 2bn.
  • The loss grew: from DKK 115m to DKK 328m (2024 → 2025).
  • Equity fell 51% (2024 → 2025), to DKK 312m.

Employees

  • 48 more employees than a year earlier: 1,294 (07/2026) against 1,246 (07/2025).

Management and owners, last 24 months

  • New in management: Alberto Santagostino (board member, 03/03/2025), Mai Iwaya (board member, 03/03/2025) and Kasper Møller (ceo, 01/04/2025) (+1).
  • Stepped down: Tomoko Miyagawa (board member, 09/01/2026), Andrea Celia Porchia (ceo, 01/04/2025) and Akira Nakamura (board member, 03/03/2025).

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 400m−DKK 200mDKK 0DKK 200mDKK 400mDKK 600m202020212022202320242025
EquityNet profit
Financial figures for AGC Biologics A/S
202020212022202320242025Change
Revenue1,455,0712,185,0332,517,9962,092,5652,016,1941,959,639−2.8%
Gross profit451,971831,905936,958501,294160,194−91,242−157%
Operating profit (EBIT)370,499733,044793,463352,214−107,026−430,031−301.8%
Profit before tax357,124734,058768,469316,034−145,332−415,924−186.2%
Net profit278,538571,735598,949243,869−115,005−328,010−185.2%
Total assets2,347,5413,140,6633,439,4263,623,6763,788,3094,050,883+6.9%
Equity339,677633,585661,277307,426640,031312,021−51.2%
Liabilities2,007,8642,507,0782,778,1493,316,2503,148,2783,738,862+18.8%
Cash and cash equivalents836,355476,897219,3959,18974,423100,742+35.4%
Average number of employees4417308949561,0191,138+11.7%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 200mDKK 0DKK 200mDKK 400mDKK 600mDKK 800mDKK 1bn202020212022202320242025
Gross profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Loss for 2 years in a row

    Net result has been negative in 2024–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

  • Equity fell sharply

    Equity fell 51% from 2024 to 2025 (DKK 640m to DKK 312m).

    How is this calculated?

    Equity has fallen by at least 30% from the previous annual report, and it was positive the year before.

  • Low equity ratio

    Equity makes up 8% of total assets in 2025.

    How is this calculated?

    Equity ÷ total assets is below 10% in the latest annual report. Banks, insurers and some industries naturally have a low ratio.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for AGC Biologics A/S
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202529/06/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202411/07/2025The companyPDF not statedXBRL
202301/01/2023 – 31/12/202304/07/2024The companyPDF not statedXBRL
202201/01/2022 – 31/12/202229/06/2023The companyPDFXBRL
202101/01/2021 – 31/12/202127/06/2022The companyPDFXBRL
202001/01/2020 – 31/12/202014/06/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
02004006008001,0001,2001,40008/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

Gross profit−DKK 91.2mNo. 55 of 57
Better than 4% of the companies in the industry
EquityDKK 312mNo. 11 of 59
Better than 83% of the companies in the industry
Number of employees1,294No. 4 of 59
Better than 95% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bn
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with 1,000 employees or more177 companies in the comparison
No. 147of 147
Better than 0%
No. 127of 177
Better than 28%
Companies that are between 15 and 29 years old24,910 companies in the comparison
No. 24,786of 24,791
Better than 0%
No. 536of 24,909
Better than 98%
All companies of type A/S18,025 companies in the comparison
No. 17,772of 17,786
Better than 0%
No. 1,020of 18,024
Better than 94%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. AGC Biologics A/S−DKK 91.2m
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. AGC Biologics A/S−DKK 328m
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. AGC Biologics A/SDKK 312m
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. AGC Biologics A/S1,294
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Asahi Glass Co., Ltd.100%
AGC Biologics A/S

Management

6 active registrations

Executive management

Executive management at AGC Biologics A/S
NameRoleAppointed
Kasper MøllerCEO01/04/2025

Board of directors

Board of directors at AGC Biologics A/S
NameRoleAppointed
Kasper MøllerBoard member01/02/2017
Tadashi MuranoChair of the board08/01/2024
Alberto SantagostinoBoard member03/03/2025
Mai IwayaBoard member03/03/2025
Yuichiro TashiroBoard member09/01/2026
Auditor
KPMG P/S
Founders
Eagle ApS, MR Bioinvest ApS, Catch The Waves ApS, Ginnigup Holding ApS, Atline Holding ApS, Provision ApS
Former management (44)
Former management at AGC Biologics A/S
NameRoleAppointedResigned
Lars HallgrenBoard member15/03/200123/03/2001
Frank HarderBoard member23/03/200131/05/2002
Mette Kirstine AggerBoard member23/03/200108/12/2004
Morten Boje MunkBoard member31/05/200229/02/2008
Björn Carl-Johan DellgrenBoard member31/05/200220/12/2005
Juha Aimo KoivurintaBoard member31/05/200231/05/2006
David KauffmannChair of the board31/05/200214/01/2014
Lone Fønss SchrøderDirector18/10/200209/12/2002
Anders VintherDirector18/10/200230/11/2006
Paul Howard Michael ToonBoard member28/12/200429/02/2008
Thomas TscherningBoard member20/12/200529/02/2008
Jesper ZeuthenDeputy board member20/12/200529/02/2008
William John HenryBoard member31/05/200629/02/2008
Christian Henrik TangeDirector30/11/200615/12/2011
Stephen John BellisDirector30/11/200610/03/2008
Thomas Léon Yves Marie BallandBoard member03/08/200729/02/2008
Stephen Andrew LehmanBoard member29/02/200801/02/2017
Mads Aage LaustsenDirector10/02/201214/01/2014
Jens Malta VellingDirector10/02/201211/12/2012
Claes Johan Robert GlassellBoard member10/02/201210/02/2012
Claes Johan Robert GlassellCEO10/02/201210/02/2012
Douglas Robert SandersDirector10/02/201201/11/2013
Claès Johan Robert GlassellBoard member10/02/201214/01/2014
Claès Johan Robert GlassellDirector10/02/201214/01/2014
Gustavo Fabio MahlerDirector10/02/201214/01/2014
Patricio Ezequiel MasseraDirector11/12/201230/06/2017
Mads Aage LaustsenChair of the board14/01/201427/06/2014
Patricio Ezequiel MasseraBoard member14/01/201430/06/2017
Jesper BrammingChair of the board27/06/201401/10/2016
Peter Klarskov VilbyChair of the board01/10/201601/02/2017
Hideyuki KurataChair of the board01/02/201702/10/2018
Ikuo MatsukuraBoard member01/02/201730/12/2019
Masahiko FukamachiBoard member01/02/201731/01/2018
Kasper MøllerDirector30/06/201704/03/2022
Yukiteru NakashitaBoard member30/06/201731/08/2018
Hiroshi NishimuraBoard member31/01/201801/09/2022
Noriyuki KomuroBoard member17/09/201802/10/2018
Hideyuki KurataBoard member03/10/201831/01/2019
Noriyuki KomuroChair of the board03/10/201808/01/2024
Hideaki KanBoard member12/02/201931/03/2021
Patricio Ezequiel MasseraBoard member04/03/202030/06/2024
Tomoko MiyagawaBoard member01/04/202109/01/2026
Andrea Celia PorchiaCEO04/03/202201/04/2025
Akira NakamuraBoard member01/09/202203/03/2025

Signing rule: Selskabet tegnes af bestyrelsens formand i forening med en direktør, af bestyrelsens formand i forening med 2 bestyrelsesmedlemmer, 2 bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.

Address and production units

4 active production units

Vandtårnsvej 83
2860 Søborg

Gladsaxe Municipality · Postcode 2860

Open in OpenStreetMap
Production units
Production unitAddressEmployeesP number
AGC Biologics A/SVandtårnsvej 83B, 2860 Søborg1,5031008349351
AGC Biologics A/SSydmarken 22, 2860 Søborg–1030123405
AGC Biologics A/SVandtårnsvej 83A, 2860 Søborg–1029830963
AGC Biologics A/SVandtårnsvej 85, 2860 Søborg–1029830939

Purpose

Selskabets formål er at drive virksomhed, som omfatter proces- og teknologiudvikling, kontraktproduktion, konsulent- og andre serviceydelser indenfor det bioteknologiske område samt forskning, udvikling og fremstilling af medicinalprodukter, og dermed forbunden virksomhed.

The purpose is quoted from the register in Danish.

Changes year by year

121 registered events
20263 changesaccounts 1 · management 2
  • Annual report for 2025 published
  • Yuichiro Tashiro appointed board member
  • Tomoko Miyagawa stepped down as board member
20256 changesaccounts 1 · management 5
  • Annual report for 2024 published
  • Kasper Møller appointed ceo
  • Andrea Celia Porchia stepped down as ceo
  • Mai Iwaya appointed board member
  • Alberto Santagostino appointed board member
  • Akira Nakamura stepped down as board member
20244 changesaccounts 1 · management 3
  • Annual report for 2023 published
  • Patricio Ezequiel Massera stepped down as board member
  • Tadashi Murano appointed chair of the board
  • Noriyuki Komuro stepped down as chair of the board
20231 changeaccounts 1
  • Annual report for 2022 published
20225 changesmanagement 4 · accounts 1
  • Akira Nakamura appointed board member
  • Hiroshi Nishimura stepped down as board member
  • Annual report for 2021 published
  • Andrea Celia Porchia appointed ceo
  • Kasper Møller stepped down as director
20213 changesaccounts 1 · management 2
  • Annual report for 2020 published
  • Tomoko Miyagawa appointed board member
  • Hideaki Kan stepped down as board member
20201 changemanagement 1
  • Patricio Ezequiel Massera appointed board member
20193 changesmanagement 3
  • Ikuo Matsukura stepped down as board member
  • Hideaki Kan appointed board member
  • Hideyuki Kurata stepped down as board member
201810 changesname 1 · address 1 · management 8
  • Name changed from CMC BIOLOGICS A/S to AGC Biologics A/S
  • Moved to Vandtårnsvej 83, 2860 Søborg
  • Noriyuki Komuro appointed chair of the board
  • Hideyuki Kurata appointed board member
  • Noriyuki Komuro stepped down as board member
  • Hideyuki Kurata stepped down as chair of the board
  • Noriyuki Komuro appointed board member
  • Yukiteru Nakashita stepped down as board member
  • Hiroshi Nishimura appointed board member
  • Masahiko Fukamachi stepped down as board member
201714 changesmanagement 10 · ownership 4
  • Kasper Møller appointed director
  • Yukiteru Nakashita appointed board member
  • Patricio Ezequiel Massera stepped down as board member
  • Patricio Ezequiel Massera stepped down as director
  • Ikuo Matsukura appointed board member
  • Kasper Møller appointed board member
  • Masahiko Fukamachi appointed board member
  • Hideyuki Kurata appointed chair of the board
  • Peter Klarskov Vilby stepped down as chair of the board
  • Stephen Andrew Lehman stepped down as board member
  • Asahi Glass Co., Ltd. registered as owner (100%)
  • CMC Biologics III S.C.S. is no longer registered as owner
  • CMC Biologics S.à r.l. is no longer registered as owner
  • CMC Biologics S.à r.l. registered as owner (5%)
20162 changesmanagement 2
  • Peter Klarskov Vilby appointed chair of the board
  • Jesper Bramming stepped down as chair of the board
20151 changeownership 1
  • CMC Biologics III S.C.S. registered as owner (100%)
20149 changesmanagement 9
  • Jesper Bramming appointed chair of the board
  • Mads Aage Laustsen stepped down as chair of the board
  • Patricio Ezequiel Massera appointed board member
  • Mads Aage Laustsen appointed chair of the board
  • Mads Aage Laustsen stepped down as director
  • Gustavo Fabio Mahler stepped down as director
  • Claès Johan Robert Glassell stepped down as director
  • Claès Johan Robert Glassell stepped down as board member
  • David Kauffmann stepped down as chair of the board
20131 changemanagement 1
  • Douglas Robert Sanders stepped down as director
201212 changesmanagement 12
  • Patricio Ezequiel Massera appointed director
  • Jens Malta Velling stepped down as director
  • Mads Aage Laustsen appointed director
  • Gustavo Fabio Mahler appointed director
  • Claès Johan Robert Glassell appointed director
  • Claès Johan Robert Glassell appointed board member
  • Douglas Robert Sanders appointed director
  • Claes Johan Robert Glassell appointed ceo
  • Claes Johan Robert Glassell stepped down as ceo
  • Claes Johan Robert Glassell appointed board member
  • Claes Johan Robert Glassell stepped down as board member
  • Jens Malta Velling appointed director
20111 changemanagement 1
  • Christian Henrik Tange stepped down as director
200812 changescapital 2 · management 8 · name 1 · industry 1
  • Share capital changed from 35,546,990 DKK to 42,852,973 DKK
  • Stephen John Bellis stepped down as director
  • Name changed from CMC BIOPHARMACEUTICALS A/S to CMC BIOLOGICS A/S
  • Share capital changed from 22,678,994 DKK to 35,546,990 DKK
  • Stephen Andrew Lehman appointed board member
  • Thomas Léon Yves Marie Balland stepped down as board member
  • William John Henry stepped down as board member
  • Thomas Tscherning stepped down as board member
  • Jesper Zeuthen stepped down as deputy board member
  • Paul Howard Michael Toon stepped down as board member
  • Morten Boje Munk stepped down as board member
  • Industry changed to Manufacture of pharmaceutical preparations (212000)
20072 changescapital 1 · management 1
  • Share capital changed from 20,870,886 DKK to 22,678,994 DKK
  • Thomas Léon Yves Marie Balland appointed board member
20065 changesmanagement 5
  • Christian Henrik Tange appointed director
  • Stephen John Bellis appointed director
  • Anders Vinther stepped down as director
  • William John Henry appointed board member
  • Juha Aimo Koivurinta stepped down as board member
20053 changesmanagement 3
  • Thomas Tscherning appointed board member
  • Jesper Zeuthen appointed deputy board member
  • Björn Carl-Johan Dellgren stepped down as board member
20043 changescapital 1 · management 2
  • Share capital changed from 10,932,703 DKK to 20,870,886 DKK
  • Paul Howard Michael Toon appointed board member
  • Mette Kirstine Agger stepped down as board member
20032 changesaddress 1 · capital 1
  • Moved to Vandtårnsvej 83, 2860 Søborg
  • Share capital changed from 7,932,703 DKK to 10,932,703 DKK
200210 changesmanagement 8 · name 1 · capital 1
  • Lone Fønss Schrøder stepped down as director
  • Name changed from CMC BIOTECH A/S to CMC BIOPHARMACEUTICALS A/S
  • Anders Vinther appointed director
  • Lone Fønss Schrøder appointed director
  • Share capital changed from 3,327,703 DKK to 7,932,703 DKK
  • Björn Carl-Johan Dellgren appointed board member
  • David Kauffmann appointed chair of the board
  • Juha Aimo Koivurinta appointed board member
  • Morten Boje Munk appointed board member
  • Frank Harder stepped down as board member
20018 changesaddress 1 · capital 2 · management 4 · founded 1
  • Moved to Fruebjergvej 3, 2100 København Ø
  • Share capital changed from 1,976,351 DKK to 3,327,703 DKK
  • Share capital changed from 625,000 DKK to 1,976,351 DKK
  • Frank Harder appointed board member
  • Mette Kirstine Agger appointed board member
  • Lars Hallgren stepped down as board member
  • Registered as CMC BIOTECH A/S
  • Lars Hallgren appointed board member

Related companies

Same industry in Gladsaxe

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 23/10/2026.

View in CVRReport a correction